Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species

Filoviruses cause sporadic but highly lethal outbreaks of hemorrhagic fever in Africa in the human population. Currently, no drug or vaccine is available for treatment or prevention. A previous study with a vaccine candidate based on the low seroprevalent adenoviruses 26 and 35 (Ad26 and Ad35) was s...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2012-12, Vol.7 (12), p.e44115-e44115
Hauptverfasser:	Zahn, Roland, Gillisen, Gert, Roos, Anna, Koning, Marina, van der Helm, Esmeralda, Spek, Dirk, Weijtens, Mo, Grazia Pau, Maria, Radošević, Katarina, Weverling, Gerrit Jan, Custers, Jerome, Vellinga, Jort, Schuitemaker, Hanneke, Goudsmit, Jaap, Rodríguez, Ariane
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenoviridae - genetics Adenoviridae - immunology Adenoviruses Analysis Animals Antibodies, Viral - genetics Antibodies, Viral - immunology Antigens Biology Cladistic analysis Cross Reactions Ebola Vaccines - genetics Ebola Vaccines - immunology Ebola virus Ebolavirus Epidemics Expression vectors Female Fever Filoviridae - immunology Genetic Vectors Glycoproteins Hemorrhage Hemorrhagic fever Hemorrhagic Fever, Ebola - immunology Hemorrhagic Fever, Ebola - prevention & control Homology Human populations Immune response Immune response (cell-mediated) Immune response (humoral) Immune system Immunity Immunity, Humoral - immunology Immunology Infections Infectious diseases Ligands Lymphocytes T Marburg virus disease Medical research Medicine Mice Mice, Inbred BALB C Neural networks Outbreaks Pathogens Phylogenetics Phylogeny Primates Protection and preservation Species Studies T cells T-Lymphocytes - immunology Vaccination Vaccines Veterinary Science Viral diseases Viral proteins Viral Vaccines - genetics Viral Vaccines - immunology Virology Viruses
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!